New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction (Q38837866)

6 September 2017

1 reference

title

New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction (English)

1 reference

heart failure with reduced ejection fraction

6 September 2017

1 reference

1 reference

Shreya Patel

1

1 reference

6 September 2017

Keith Veltri

series ordinal

2

1 reference

6 September 2017

publication date

18 May 2016

1 reference

Journal of Pharmacy Practice

6 September 2017

published in

1 reference

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Volume Overload in Heart Failure: An Evidence-Based Review of Strategies for Treatment and Prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Angiotensin-neprilysin inhibition versus enalapril in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Acute precipitants of congestive heart failure exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Trends in comorbidity, disability, and polypharmacy in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Early and long-term outcomes of heart failure in elderly persons, 2001-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Potential impact of optimal implementation of evidence-based heart failure therapies on mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

HCN channels and heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Ivabradine, coronary artery disease, and heart failure: beyond rhythm control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

The "Modern" View of Heart Failure: How Did We Get Here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Ivabradine: A Unique and Intriguing Medication for Treating Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Novel If current inhibitor ivabradine: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

Ivabradine in heart failure--no paradigm SHIFT…yet

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016649123

21 January 2018

Identifiers

DOI

10.1177/0897190016649123

0 references

1 reference